Clearly a major proportion of the profits for any pharmaceutical currently comes from the US, regardless of where those drugs were <i>developed</i>. If the global profits for pharmaceuticals are curtailed because the US stops paying a premium it seems foolish to say that the profit motive wouldn&#x27;t be impacted in regards to spending on pharmaceutical R&amp;D.